Madaudo Cristina, Di Lisi Daniela, Cannatà Antonio, Manfrè Federica, Vullo Celeste, Santoro Marco, Botta Ciro, Mancuso Salvatrice, Siragusa Sergio, Galassi Alfredo Ruggero, Novo Giuseppina
Cardiology Unit, University Hospital 'Paolo Giaccone', Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy.
British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK.
ESC Heart Fail. 2025 Apr;12(2):1447-1454. doi: 10.1002/ehf2.15165. Epub 2025 Jan 9.
Knowledge of the effects of sex in cardio-oncology is limited, particularly in patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML). This study aims to evaluate the influence of gender differences on the incidence of cardiovascular toxicity in patients with CML.
The study population consisted of 148 patients (45% women, mean age: 58 ± 14.2 years) diagnosed with CML treated with TKIs. The HFA-ICOS score estimated cardiovascular risk. The HFA-ICOS score revealed that 12% of men and 6% of women were categorized as very high risk while 45% of men and 50% of women fell into the high-risk group. Myocardial ischaemia, peripheral artery disease, venous thromboembolism, pulmonary hypertension and new-onset arterial hypertension during treatment with TKIs were recorded.
The incidence of global events between men and women was comparable (35% vs 32%, P = 0.68). There were 33% who experienced a cardiovascular event during TKI therapy, with a significant sex difference in arterial thrombosis incidence (P = 0.02) and venous thrombosis incidence (P = 0.02). Patients treated with ponatinib had a 41% event rate, followed by nilotinib (32%) and imatinib (32%). The HFA-ICOS score demonstrated greater predictive efficacy for events in the female group [area under the curve (AUC) = 0.797] compared with the male group (AUC = 0.537). Very high [hazard ratio (HR) 3.07; confidence interval (CI) 1.11, 8.47 P = 0.03] and high (HR 3.29; CI 1.17, 9.26 P = 0.02) HFA-ICOS scores were associated with increased event risk, particularly in women. Diabetes was women's strongest predictor of events (HR 5.40; CI 1.37, 21.3 P = 0.01).
Our study showed a similar frequency of cardiovascular events between men and women. Accurate cardiovascular risk stratification with HFA-ICOS score in cancer patients is crucial. Diabetes and the HFA-ICOS score were significant predictors of events in the female groups. A sex approach in clinical practice could be pursued to improve the appropriateness of care.
关于性别在心脏肿瘤学中的影响的认识有限,尤其是在接受酪氨酸激酶抑制剂(TKIs)治疗的慢性髓性白血病(CML)患者中。本研究旨在评估性别差异对CML患者心血管毒性发生率的影响。
研究人群包括148例诊断为CML并接受TKIs治疗的患者(45%为女性,平均年龄:58±14.2岁)。HFA-ICOS评分用于评估心血管风险。HFA-ICOS评分显示,12%的男性和6%的女性被归类为极高风险,而45%的男性和50%的女性属于高风险组。记录了TKIs治疗期间的心肌缺血、外周动脉疾病、静脉血栓栓塞、肺动脉高压和新发动脉高血压情况。
男性和女性总体事件的发生率相当(35%对32%,P=0.68)。33%的患者在TKI治疗期间发生了心血管事件,动脉血栓形成发生率(P=0.02)和静脉血栓形成发生率(P=0.02)存在显著性别差异。接受波纳替尼治疗的患者事件发生率为41%,其次是尼罗替尼(32%)和伊马替尼(32%)。与男性组(曲线下面积[AUC]=0.537)相比,HFA-ICOS评分对女性组事件的预测效能更高[AUC=0.797]。极高(风险比[HR]3.07;置信区间[CI]1.11,8.47,P=0.03)和高(HR 3.29;CI 1.17,9.26,P=0.02)的HFA-ICOS评分与事件风险增加相关,尤其是在女性中。糖尿病是女性事件的最强预测因素(HR 5.40;CI 1.37,21.3,P=0.01)。
我们的研究表明男性和女性心血管事件的发生频率相似。在癌症患者中使用HFA-ICOS评分进行准确的心血管风险分层至关重要。糖尿病和HFA-ICOS评分是女性组事件的重要预测因素。在临床实践中可采用针对性别的方法来提高治疗的适宜性。